Oncology Division (CIMA), and Department of Biochemistry and Genetics (School of Science), University of Navarra, Pamplona, Spain,
Adv Exp Med Biol. 2014;772:229-62. doi: 10.1007/978-1-4614-5915-6_11.
Complement is a central part of the immune system that has developed as a first defense against non-self cells. Neoplastic transformation is accompanied by an increased capacity of the malignant cells to activate complement. In fact, clinical data demonstrate complement activation in cancer patients. On the basis of the use of protective mechanisms by malignant cells, complement activation has traditionally been considered part of the body's immunosurveillance against cancer. Inhibitory mechanisms of complement activation allow cancer cells to escape from complement-mediated elimination and hamper the clinical efficacy of monoclonal antibody-based cancer immunotherapies. To overcome this limitation, many strategies have been developed with the goal of improving complement-mediated effector mechanisms. However, significant work in recent years has identified new and surprising roles for complement activation within the tumor microenvironment. Recent reports suggest that complement elements can promote tumor growth in the context of chronic inflammation. This chapter reviews the data describing the role of complement activation in cancer immunity, which offers insights that may aid the development of more effective therapeutic approaches to control cancer.
补体是免疫系统的核心部分,它作为针对非自身细胞的第一道防线而发展。肿瘤转化伴随着恶性细胞激活补体的能力增强。事实上,临床数据表明癌症患者存在补体激活。基于恶性细胞对保护机制的利用,补体激活传统上被认为是机体对癌症免疫监视的一部分。补体激活的抑制机制使癌细胞能够逃避补体介导的消除,并阻碍基于单克隆抗体的癌症免疫疗法的临床疗效。为了克服这一限制,已经开发了许多策略,旨在改善补体介导的效应机制。然而,近年来的大量工作确定了补体激活在肿瘤微环境中的新的、令人惊讶的作用。最近的报告表明,补体成分可以在慢性炎症的情况下促进肿瘤生长。本章综述了描述补体激活在癌症免疫中的作用的数据,这些数据提供了可能有助于开发更有效的控制癌症的治疗方法的见解。